An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting-Reference-Cited by-同舟云学术

An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting

Published:1997-01 Issue:1 Volume:33 Page:66-74
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Jantunen I.T.,Kataja V.V.,Muhonen T.T.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference62 articles.

1. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting;Cubeddu;N Engl J Med,1990

2. Urinary serotonin metabolite excretion during cisplatin chemotherapy;Wilder-Smith;Cancer,1993

3. The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action;Andrews;Eur J Cancer,1993

4. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine m-receptor antagonism;Miner;Br J Pharmacol,1986

5. Are all 5-HT3 receptor antagonists the same?;Andrews;Eur J Cancer,1992

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial;The Korean Journal of Internal Medicine;2023-05-01

2. How Should Medications Be Initiated and Titrated to Reduce Acute and Delayed Nausea and Vomiting in the Setting of Chemotherapy?;Evidence-Based Practice of Palliative Medicine;2023

3. Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2021-05-15

4. Cannabinoids as antiemetics: everything that’s old is new again;Annals of Oncology;2020-11

5. Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy;PHARMAZIE;2018